All In Biotech

Drug Trial Radar · NCT07111546

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 02(BTC&HCC)]

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Dec 26, 2027

Study completion Dec 26, 2027

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Shanghai Zhongshan Hospital
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.

Conditions

  • Advanced Solid Tumour

Interventions

  • LBL-024 for InjectionDrug

    Intravenous infusion.

  • Cisplatin InjectionDrug

    Intravenous infusion.

  • Gemcitabine Hydrochloride for InjectionDrug

    Intravenous infusion.

  • Bevacizumab InjectionDrug

    Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • People's Hospital of Hunan Province

    Changsha, Hunan, China · Not yet recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Xi 'an International Medical Center Hospital

    Xi’an, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.